A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01945775
Recruitment Status : Active, not recruiting
First Posted : September 19, 2013
Last Update Posted : March 21, 2018
Medivation is now a wholly owned subdiary of Pfizer, Inc.
Information provided by (Responsible Party):

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Primary Completion Date : September 15, 2017
  Estimated Study Completion Date : December 27, 2019